Factors Associated With Acute Kidney Injury in Children Receiving Vancomycin

Annals of Pharmacotherapy

Volumn 48, Issue 12, 2014, Pages 1555-1562

  Sinclair, Elizabeth A ^a   Yenokyan, Gayane ^b   McMunn, Andrea ^c   Fadrowski, Jeffrey J ^d   Milstone, Aaron M ^d   Lee, Carlton K K ^d  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c KAISER PERMANENTE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

acute kidney injury; adverse drug event; nephrotoxicity; pediatrics; vancomycin

Indexed keywords

METHOTREXATE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACUTE KIDNEY FAILURE; ADOLESCENT; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; CENTRAL NERVOUS SYSTEM INFECTION; CHILD; CHILDHOOD DISEASE; CONTROLLED STUDY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INFANT; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PEDIATRIC HOSPITAL; PNEUMONIA; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; RETROSPECTIVE STUDY; RISK ASSESSMENT; SKIN INFECTION; SOFT TISSUE INFECTION; ACUTE KIDNEY INJURY; CHEMICALLY INDUCED; HOSPITAL; ODDS RATIO; PRESCHOOL CHILD; RISK FACTOR; TERTIARY CARE CENTER; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; ACUTE KIDNEY INJURY; ADOLESCENT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HOSPITALS, PEDIATRIC; HUMANS; INCIDENCE; INFANT; MALE; ODDS RATIO; RETROSPECTIVE STUDIES; RISK FACTORS; TERTIARY CARE CENTERS; VANCOMYCIN;

EID: 84921496579     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028014549185     Document Type: Article

References (48)

1. Rybak M,Lomaestro B,Rotschafer JC, et al.Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.Am J Health Syst Pharm. 2009;66:82-98
2. Cies JJ,Shankar V.Nephrotoxicity in patients with vancomycin trough concentrations of 15-20 µg/ml in a pediatric intensive care unit.Pharmacotherapy. 2013;33:392-400
3. Lake Forest, IL: Hospira Inc; 2008:
4. Piro CC,Crossno CL,Collier A,Ho R,Koyama T,Frangoul H.Initial vancomycin dosing in pediatric oncology and stem cell transplant patients.J Pediatr Hematol Oncol. 2009;31:3-7
5. Frymoyer A,Hersh AL,Benet LZ,Guglielmo BJ.Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate.Pediatr Infect Dis J. 2009;28:398-402
6. Benner KW,Worthington MA,Kimberlin DW,Hill K,Buckley K,Tofil NM.Correlation of vancomycin dosing to serum concentrations in pediatric patients: a retrospective database review.J Pediatr Pharmacol Ther. 2009;14:86-93
7. Frymoyer A,Guglielmo BJ,Wilson SD,Scarpace SB,Benet LZ,Hersh AL.Impact of a hospitalwide increase in empiric pediatric vancomycin dosing on initial trough concentrations.Pharmacotherapy. 2011;31:871-876
8. Eiland LS,English TM,Eiland EH.Assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients.Ann Pharmacother. 2011;45:582-589
9. Liu C,Bayer A,Cosgrove SE, et al.Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.Clin Infect Dis. 2011;52:1-38
10. Vancomycin: pediatric Lexi-Drugs. Hudson, OH: Lexi-Comp, Inc. http://www.crlonline.com. Accessed September 28, 2010.
11. Greenwood Village, CO: Thomson Reuters;
12. Moellering RC.Vancomycin: a 50-year reassessment.Clin Infect Dis. 2006;42:S3-S4
13. Griffith RS.Introduction to vancomycin.Rev Infect Dis. 1981;3:S200-S203
14. Farber BF,Moellering RC.Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981.Antimicrob Agents Chemother. 1983;23:138-141
15. Nahata M.Lack of nephrotoxicity in pediatric patients receiving concurrent vancomycin and aminoglycoside therapy.Chemotherapy. 1987;33:302-304
16. Goren MP,Baker DK,Shenep JL.Vancomycin does not enhance amikacin-induced tubular nephrotoxicity in children.Pediatr Infect Dis J. 1989;8:278-282
17. Schneider J,Khemani R,Grushkin C,Bart R.Serum creatinine as stratified in the RIFLE score for acute kidney injury is associated with mortality and length of stay for children in the pediatric intensive care unit.Crit Care Med. 2010;38:933-939
18. Hidayat LK,Hsu DI,Quist R,Shriner KA,Wong-Beringer A.High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections.Arch Intern Med. 2006;166:2138-2144
19. Jeffres MN,Isakow W,Doherty JA,Micek ST,Kollef MH.A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia.Clin Ther. 2007;29:1107-1115
20. Lodise TP,Lomaestro B,Graves J,Drusano GL.Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity.Antimicrob Agents Chemother. 2008;52:1330-1336
21. Lodise TP,Patel N,Lomaestro BM,Rodvold KA,Drusano GL.Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients.Clin Infect Dis. 2009;49:507-514
22. Hermsen ED,Hanson M,Sankaranarayanan J,Stoner JA,Florescu MC,Rupp ME.Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections.Expert Opin Drug Saf. 2010;9:9-14
23. Pritchard L,Baker C,Leggett J,Sehdev P,Brown A,Bayley KB.Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity.Am J Med. 2010;123:1143-1149
24. Bosso JA,Nappi J,Rudisill C, et al.Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial.Antimicrob Agents Chemother. 2011;55:5475-5479
25. Minejima E,Choi J,Beringer P,Lou M,Tse E,Wong-Beringer A.Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients.Antimicrob Agents Chemother. 2011;7:3278-3283
26. van Hal SJ,Paterson DL,Lodise TP.Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter.Antimicrob Agents Chemother. 2013;57:734-744
27. McKamy S,Hernandez E,Jahng M,Moriwaki T,Deveikis A,Le J.Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children.J Pediatr. 2011;158:422-426
28. Totapally BR,Machado J,Lee H,Paredes A,Raszynski A.Acute kidney injury during vancomycin therapy in critically ill children.Pharmacotherapy. 2013;33:598-602
29. Schwartz GJ,Haycock MB,Edelmann CM,Spitzer A.A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine.Pediatrics. 1976;58:259-263
30. Schwartz GJ,Feld LG,Langford DJ.A simple estimation of glomerular filtration rate in full-term infants during the first year of life.J Pediatr. 1984;104:849-854
31. Schwartz GJ,Gautheir B.A simple estimate of glomerular filtration rate in adolescent boys.J Pediatr. 1985;106:522-526
32. Cairo MS,Bishop M.Tumour lysis syndrome: new therapeutic strategies and classification.Br J Haematol. 2004;127:3-11
33. Akcan-Arikan A,Zappitelli M,Loftis LL,Washburn KK,Jefferson LS,Goldstein SL.Modified RIFLE criteria in critically ill children with AKI.Kidney Int. 2007;71:1028-1035
34. Fawcett T.An introduction to ROC analysis.Pattern Recognit Lett. 2006;27:861-874
35. Le J,Bradley JS,Murray W, et al.Improved vancomycin dosing in children using area under the curve.Pediatr Infect Dis J. 2013;32:e155-e163
36. Fisher BT,Zaoutis TE,Leckerman KH,Localio R,Aplenc R.Risk factors for renal failure in pediatric patients with acute myeloid leukemia: a retrospective cohort study.Pediatr Blood Cancer. 2010;55:655-661
37. Knoderer CA,Nichols KR,Lyon KC,Veverka MM,Wilson AC.Are elevated vancomycin serum trough concentrations achieved within the first 7 days of therapy associated with acute kidney injury in children?.J Pediatr Infect Dis Soc. 2014;3:127-131
38. Moffett BS,Kim S,Edwards M.Vancomycin nephrotoxicity may be overstated.J Pediatr. 2011;158:865-866
39. Staples A,LeBlond R,Watkins S,Wong C,Brandt J.Validation of the revised Schwartz estimating equation in a predominately non-CKD population.Pediatr Nephrol. 2010;25:2321-2326
40. Plotz FB,Bouma AB,van Wijk JAE,Kneyber MCJ,Bokenkamp A.Pediatric acute kidney injury in the ICU: an independent evaluation of pRIFLE criteria.Intensive Care Med. 2008;34:1713-1717
41. Moffett BS,Goldstein SL.Acute kidney injury and increasing nephrotoxic-medication exposure in noncritically-ill children.Clin J Am Soc Nephrol. 2011;6:856-863
42. Hsu CW,Symons JM.Acute kidney injury: can we improve prognosis?.Pediatr Nephrol. 2010;25:2401-2412
43. Zappitelli M,Parikh CR,Akcan-Arikan A,Washburn KK,Moffett BS,Goldstein SL.Ascertainment and epidemiology of acute kidney injury varies with definition interpretation.Clin J Am Soc Nephrol. 2008;3:948-954
44. Slater MB,Anand V,Uleryk EM,Parshuram CS.A systematic review of RIFLE criteria in children and its application and association with measures of mortality and morbidity.Kidney Int. 2012;81:791-798
45. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.Am J Kidney Dis. 2002;39:s1-s266
46. Hellwig T,Hammerquist R,Loecker B,Shields J.Retrospective evaluation of the incidence of vancomycin and/or piperacillin-tazobactam induced acute renal failure [abstract].Crit Care Med. 2011;39 (S12): 301
47. Min E,Box K,Lange J, et al.Acute kidney injury in patients receiving concomitant vancomycin and piperacillin/tazobactam [abstract].Crit Care Med. 2011;39:714
48. Misurac JM,Knoderer CA,Leiser J,Nailescu C,Wilson AC,Andreoli SP.Nonsteroidal anti-inflammatory drugs are an important cause of acute kidney injury in children.J Pediatr. 2013;162:1153-1159